• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    11/24/23 12:31:07 PM ET
    $BPTS
    $EVLO
    $GYRE
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BPTS alert in real time by email

    Gainers

    • GeneDx Hldgs (NASDAQ:WGS) stock moved upwards by 39.7% to $1.97 during Friday's regular session. The market value of their outstanding shares is at $50.9 million.
    • Scilex Holding (NASDAQ:SCLX) stock increased by 27.72% to $1.29. The company's market cap stands at $123.6 million.
    • Modular Medical (NASDAQ:MODD) shares rose 21.69% to $1.29. The company's market cap stands at $27.2 million.
    • Sight Sciences (NASDAQ:SGHT) stock rose 18.0% to $2.95. The company's market cap stands at $143.8 million.
    • Gyre Therapeutics (NASDAQ:GYRE) shares increased by 17.62% to $18.95. The company's market cap stands at $1.4 billion.
    • Pasithea Therapeutics (NASDAQ:KTTA) stock moved upwards by 16.66% to $0.35. The market value of their outstanding shares is at $7.2 million.

    Losers

    • Evelo Biosciences (NASDAQ:EVLO) stock fell 19.7% to $0.49 during Friday's regular session. The market value of their outstanding shares is at $9.2 million.
    • Leap Therapeutics (NASDAQ:LPTX) shares fell 12.24% to $2.51. The market value of their outstanding shares is at $64.1 million.
    • SenesTech (NASDAQ:SNES) stock declined by 11.6% to $2.17.
    • Virios Therapeutics (NASDAQ:VIRI) stock decreased by 11.0% to $0.61. The market value of their outstanding shares is at $11.7 million.
    • MSP Recovery (NASDAQ:LIFW) shares fell 10.42% to $4.58. The company's market cap stands at $65.5 million.
    • Biophytis (NASDAQ:BPTS) stock declined by 9.0% to $0.72. The company's market cap stands at $6.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BPTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BPTS
    $EVLO
    $GYRE
    $KTTA

    CompanyDatePrice TargetRatingAnalyst
    GeneDx Holdings Corp.
    $WGS
    2/9/2026$155.00Equal Weight → Overweight
    Wells Fargo
    Sight Sciences Inc.
    $SGHT
    1/5/2026$9.00Neutral → Overweight
    Piper Sandler
    GeneDx Holdings Corp.
    $WGS
    10/20/2025$155.00Buy
    Canaccord Genuity
    Gyre Therapeutics Inc.
    $GYRE
    10/10/2025$16.00Buy
    Jefferies
    Gyre Therapeutics Inc.
    $GYRE
    8/26/2025$18.00Buy
    H.C. Wainwright
    Sight Sciences Inc.
    $SGHT
    8/8/2025$5.00Hold → Buy
    Lake Street
    GeneDx Holdings Corp.
    $WGS
    7/9/2025$110.00Overweight
    Piper Sandler
    GeneDx Holdings Corp.
    $WGS
    5/15/2025$88.00Buy
    Guggenheim
    More analyst ratings

    $BPTS
    $EVLO
    $GYRE
    $KTTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Meister Keith A. bought $13,460,090 worth of shares (169,521 units at $79.40) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/5/26 7:19:34 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $BPTS
    $EVLO
    $GYRE
    $KTTA
    SEC Filings

    View All

    Modular Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Modular Medical, Inc. (0001074871) (Filer)

    3/6/26 4:16:02 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Sight Sciences Inc.

    10-K - Sight Sciences, Inc. (0001531177) (Filer)

    3/4/26 4:19:08 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Sight Sciences, Inc. (0001531177) (Filer)

    3/4/26 4:08:05 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $BPTS
    $EVLO
    $GYRE
    $KTTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing

    New data shows up to 61% reduction in healthcare costs for children with neurodevelopmental disorders in the 12 months following ExomeDx™ and GenomeDx™ testing, regardless of the test result GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced findings from the Genetic Sequencing Analysis has Value in Economic Savings (SAVES)-Kids Study, a real-world data Health Economics and Outcomes Research (HEOR) analysis led by GeneDx that focuses on the economic impact of whole exome sequencing (WES) and whole genome sequencing (WGS) in children with neurodevelopmental disorders, like epilepsy and developmental delay and in

    3/11/26 5:00:00 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

    Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (NASDAQ:ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing Program is designed to expand access to GeneDx's industry-leading ExomeDx™ test for patients with suspected Niemann-Pick disease type C, helping clinicians reach accurate diag

    3/10/26 8:30:00 AM ET
    $WGS
    $ZVRA
    Retail: Computer Software & Peripheral Equipment
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $BPTS
    $EVLO
    $GYRE
    $KTTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by GeneDx Holdings Corp.

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/11/26 4:28:48 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    SEC Form 4 filed by GeneDx Holdings Corp.

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/11/26 4:26:37 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    CHIEF FINANCIAL OFFICER Feeley Kevin was granted 1,986 shares, increasing direct ownership by 11% to 20,660 units (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/9/26 7:56:01 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $BPTS
    $EVLO
    $GYRE
    $KTTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GeneDx upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded GeneDx from Equal Weight to Overweight and set a new price target of $155.00

    2/9/26 6:58:22 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Sight Sciences upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Sight Sciences from Neutral to Overweight and set a new price target of $9.00

    1/5/26 8:36:47 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Canaccord Genuity initiated coverage on GeneDx with a new price target

    Canaccord Genuity initiated coverage of GeneDx with a rating of Buy and set a new price target of $155.00

    10/20/25 8:45:12 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $BPTS
    $EVLO
    $GYRE
    $KTTA
    Leadership Updates

    Live Leadership Updates

    View All

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care

    Recognized neonatologist and payer-strategy leader joins GeneDx to expand earlier diagnosis and establish genomics as a standard of care across healthcare GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights today announced Linda Genen, MD, MPH as Chief Medical Officer to further strengthen the company's commitment to delivering earlier answers and better outcomes for families through genomic insights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106493899/en/GeneDx Names Dr. Linda Genen, MD, MPH as Chief Medical Officer In her role at GeneDx, Dr. Genen will oversee Medical and Cli

    1/6/26 8:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

    PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced that it has appointed Kasowitz LLP and its founding partner Marc Kasowitz as the Company's litigation and intellectual property counsel. Kasowitz LLP will advise Scilex on complex commercial litigation, patent litigation, intellectual property enforcement and defense, licensing matters, and strategic intellectual property governance as the C

    1/2/26 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BPTS
    $EVLO
    $GYRE
    $KTTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13D/A filed by Modular Medical Inc.

    SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)

    11/25/24 7:18:33 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/20/24 9:36:13 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $BPTS
    $EVLO
    $GYRE
    $KTTA
    Financials

    Live finance-specific insights

    View All

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance

    MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the fourth quarter and full year ended December 31, 2025 and initiated financial guidance for full year 2026.   Recent Financial Highlights Generated fourth quarter 2025 total revenue of $20.4 million, an increase of 7% compared to the same period in the prior year, and full year 2025 total revenue of $77.4 million, a decrease of 3% compared to full year 2

    3/4/26 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

    Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024 benefit) Accelerated exome and genome volume growth to 34% year-over-year Reported fourth quarter 2025 adjusted gross margin1 of 71% Reported fourth quarter 2025 adjusted net income1 of $4.4 million Reaffirmed full year 2026 guidance of $540 to $555 million in revenue with 33-35% exome and genome growth GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for t

    2/23/26 6:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology